The prognostic significance of preoperative tumor marker (CEA, CA15-3) elevation in breast cancer patients: data from the Korean Breast Cancer Society Registry

ConclusionPreoperative CEA and CA15-3 levels showed varying prognostic ability according to breast cancer subtype. Preoperative CA15-3 and CEA elevation are significant prognostic factors for luminal breast cancer, but they were not significant factors for TNBC.
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research

Related Links:

Condition:   Breast Cancer Interventions:   Drug: nivolumab;   Drug: ipilimumab;   Drug: nab-paclitaxel Sponsor:   Bristol-Myers Squibb Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Metastatic breast cancer highlights from ESMO 2019 confirm that CDK4/6 inhibition gives survival benefit in HR+/HER2- breast cancer and that immunotherapy is active in the neoadjuvant setting in TNBC.Medscape
Source: Medscape Today Headlines - Category: Consumer Health News Tags: None ReCAP Source Type: news
No abstract available
Source: Oncology Times - Category: Cancer & Oncology Tags: News Source Type: research
Authors: Matsui A, Murata Y, Masuda N, Mori K, Takahashi M, Yamashiro K, Aogi K, Maeda S, Itou M, Ozaki S, Kuraoka K, Satou Y, Ichihara S, Tokunaga E, Taguchi K, Watanabe T, Suzuki H, Nagayama A, Nishimura R Abstract Hormone receptor and human epidermal growth factor receptor 2 (HER2) protein tests in metastatic breast cancer tissue are recommended in the guidelines of the American Society of Clinical Oncology/American Pathology Association. As part of a multi-institutional study by the National Hospital Organization, we conducted an investigation to examine these molecular markers, using cytological specimens as a...
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
The combined use of a CDK4/6 inhibitor with endocrine therapy yielded a 9.4-month median OS benefit among patients.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Source Type: news
ConclusionsPredictive markers displayed a yearly similar distribution in breast cancer cases independently of grading or of intrinsic subtypes. These results point to a qualitative high performance of predictive marker assessment in breast cancer, corresponding to expected on average positivity rate per marker and per year. It is recommended to monitor positivity rate of ER, PR, Ki67 and Her2 yearly or periodically to comply with quality assurance requirements.
Source: Journal of Cancer Research and Clinical Oncology - Category: Cancer & Oncology Source Type: research
Publication date: Available online 16 October 2019Source: European Journal of RadiologyAuthor(s): Bas H.M. van der Velden, Tycho Bismeijer, Sander Canisius, Claudette E. Loo, Esther H. Lips, Jelle Wesseling, Max A. Viergever, Lodewyk F.A. Wessels, Kenneth G.A. GilhuijsAbstractPurposeTo retrospectively explore the relation between parenchymal enhancement of the healthy contralateral breast on dynamic contrast-enhanced magnetic resonance imaging (MRI) and genomic tests for estrogen receptor (ER)-pathway activity in patients with ER-positive/HER2-negative cancer.MethodsA subset of 227 consecutively included patients with unil...
Source: European Journal of Radiology - Category: Radiology Source Type: research
ConclusionsAgreement between MS and surrogate classifications was generally poor. However, a post hoc analysis showed that a combination of HG and Ki67 could identify patients very likely to have Luminal A tumours according to MS.
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research
ConclusionsmTOR signaling is highly activated in TNBC tumors. As single rapalog treatment is insufficient to block mTOR signaling in rapalog-resistant TNBC cells, our results thus provide a potential multi-kinase inhibitor combinatorial strategy to overcome mTOR-targeted therapy resistance in TNBC cells.
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research
AstraZeneca and Daiichi Sankyo Company, Limited (Daiichi Sankyo) today announced that the US Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for [fam-] trastuzumab deruxtecan (DS-8201) and granted Priority Review.
Source: World Pharma News - Category: Pharmaceuticals Tags: Featured AstraZeneca Business and Industry Source Type: news
More News: Breast Cancer | Cancer | Cancer & Oncology | Databases & Libraries | HER2